Two life sciences tools companies. One trades at 32 times forward earnings. The other at 17 times. That’s roughly a 2x gap. And it raises a simple question: which one is the market getting wrong?
Bio-Rad Laboratories Inc. (NYSE: BIO) and Charles River Laboratories International Inc. (NYSE: CRL) both occupy essential, non-discretionary positions in the biotech and pharma supply chain. One makes diagnostic instruments and reagents. The other provides research models and drug discovery services.
But their valuations tell very different stories.
Let’s start with the basics.
Bio-Rad earned $759.9 million in net income in fiscal 2025. It has a $7.5 billion market cap and trades at 31.95x forward earnings. Revenue came in at nearly $2.6 billion, up 0.6% year-over-year. Its balance sheet is rock-solid — debt-to-equity of 0.2x, with $312 million in free cash flow.
Charles River lost $144.3 million in fiscal 2025. It has an $8.7 billion market cap and trades at 16.6x forward earnings. Revenue was just over $4.0 billion, down roughly 1% year-over-year. Its leverage is higher at 1.0x debt-to-equity, but free cash flow is stronger at $518.5 million.
So Bio-Rad is profitable and cheaper on an absolute basis ($7.5B vs. $8.7B market cap). But on earnings multiples? It’s nearly twice as expensive.
The valuation divide comes down to two things: earnings quality and earnings trajectory.
First, quality. Bio-Rad’s headline net income includes mark-to-market gains from its equity stake in Sartorius AG. Those gains are real on paper, but they’re not operating profits — they swing with the stock market. Strip them out, and the underlying earnings power looks less impressive.
Second, trajectory. This is the bigger one.
Bio-Rad is facing headwinds. Reduced U.S. federal health research funding and Middle East disruptions are pressuring its diagnostics business. Analysts expect revenue to slip to $2.57 billion in fiscal 2026, with net income dropping sharply to $225 million. The arrow is pointing down.
Charles River is in the opposite position. It’s restructuring — divesting slower businesses and focusing on higher-margin areas. Revenue will dip to $3.9 billion this year, but net income is projected to swing back to $285 million in profit, with management targeting $100 million in cost savings. The arrow is pointing up.
The market is paying Bio-Rad for where it’s been. It’s paying Charles River for where it’s going.
The short answer: probably neither is completely wrong. But Charles River looks like the better bet.
Bio-Rad’s premium makes some sense — it’s profitable, has a fortress balance sheet, and owns valuable diagnostic franchises. But 32x forward earnings for a company whose profits are expected to drop sharply? That leaves little margin for error.
Charles River’s discount also makes sense — it’s losing money now, and restructuring always carries execution risk. But at 16.6x forward earnings with a return to profitability on the horizon? The risk-reward looks more favorable.
Both companies are retooling. Both have long-term growth drivers in life sciences and drug development. But Charles River is further along in its turnaround plan, and the cheaper valuation provides a bigger cushion if things go wrong.
Risks abound on both sides. Charles River depends on international supplies of research models — vulnerable to geopolitics. Bio-Rad competes with giants like Thermo Fisher (TMO) and Danaher (DHR), and generates 60% of sales internationally.
But here’s the thing: a 2x valuation gap between two companies in the same sector can’t be perfectly right. One of them is mispriced.
And right now, the odds favor it being the cheaper one.
